Literature DB >> 31998820

Survivor and Caregiver Expectations and Preferences Regarding Lung Cancer Treatment.

Jana Wieland1, Bradford S Hoppe2, Sarah M Rausch-Osian3, Jennifer C King4, Alexandra Sierra5, John W Hiemenz6, Julie Bradley3,7, Dat C Pham6, Lisa M Jones6, Anamaria R Yeung7, Keri Hopper3, Nancy P Mendenhall3,7, Kathryn E Hitchcock7.   

Abstract

PURPOSE: Treatment success in lung cancer is no longer restricted to objective measures of disease-specific outcomes and overall survival alone but now incorporates treatment morbidity and subjective quality of life (QoL). This study reports how lung cancer patients, survivors, and caregivers define treatment success and prioritize treatment decisions.
MATERIALS AND METHODS: An online survey with both ranking and free-response questions was administered among lung cancer survivors and caregivers. Responses were used to evaluate treatment priorities, perceptions of treatment success based on Eastern Cooperative Oncology Group (ECOG) Performance Status, and troublesomeness of treatment-related toxicities.
RESULTS: Among 61 respondents (29 lung cancer survivors, 28 caregivers of survivors, and 4 who were both survivors and caregivers), cancer cure was the highest priority when making treatment decisions for 74.5% of respondents, with QoL during and after treatment ranking second and third. Seventy percent of respondents felt that treatment morbidity resulting in complete dependence on others and spending the entire day confined to bed or chair would represent unsuccessful treatment. Requiring oxygen use was ranked as a very or extremely troublesome treatment toxicity by 64%, followed by shortness of breath (62%), fatigue (49%), chronic cough (34%), and appetite loss (30%). Even with remission, a 3- to 7-day hospital admission for pneumonia during treatment was deemed an unsuccessful outcome by 30%.
CONCLUSION: This study highlights the importance of physicians discussing in detail with their lung cancer patients their desires and goals. Accounting for factors like expected performance status following treatment, troublesomeness of treatment toxicities, and hospitalization rates may help guide treatment decisions. © Copyright 2019 The Author(s).

Entities:  

Keywords:  cancer survivorship; caregiving; lung cancer; quality of life; radiation therapy

Year:  2019        PMID: 31998820      PMCID: PMC6986396          DOI: 10.14338/IJPT-19-00072.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  14 in total

1.  The learning curve in pancreatic surgery.

Authors:  Jennifer F Tseng; Peter W T Pisters; Jeffrey E Lee; Huamin Wang; Henry F Gomez; Charlotte C Sun; Douglas B Evans
Journal:  Surgery       Date:  2007-05       Impact factor: 3.982

2.  Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.

Authors:  Zhongxing Liao; J Jack Lee; Ritsuko Komaki; Daniel R Gomez; Michael S O'Reilly; Frank V Fossella; George R Blumenschein; John V Heymach; Ara A Vaporciyan; Stephen G Swisher; Pamela K Allen; Noah Chan Choi; Thomas F DeLaney; Stephen M Hahn; James D Cox; Charles S Lu; Radhe Mohan
Journal:  J Clin Oncol       Date:  2018-01-02       Impact factor: 44.544

Review 3.  The cancer patient and quality of life.

Authors:  Andrew Bottomley
Journal:  Oncologist       Date:  2002

4.  Measuring symptom distress in patients with lung cancer. A pilot study of experienced intensity and importance of symptoms.

Authors:  C Tishelman; L F Degner; B Mueller
Journal:  Cancer Nurs       Date:  2000-04       Impact factor: 2.592

5.  Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?

Authors:  Ludger Sellmann; Klaus Fenchel; Wolfram C M Dempke
Journal:  Transl Lung Cancer Res       Date:  2015-06

6.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

7.  Relationship between cancer patients' predictions of prognosis and their treatment preferences.

Authors:  J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips
Journal:  JAMA       Date:  1998-06-03       Impact factor: 56.272

8.  Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany.

Authors:  Shrividya Iyer; Gavin Taylor-Stokes; Adam Roughley
Journal:  Lung Cancer       Date:  2013-04-03       Impact factor: 5.705

9.  Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial.

Authors:  Chee Khoon Lee; Silvia Novello; Anna Rydén; Helen Mann; Tony Mok
Journal:  J Clin Oncol       Date:  2018-05-07       Impact factor: 44.544

10.  On the validity of using increases in 5-year survival rates to measure success in the fight against cancer.

Authors:  Yosef E Maruvka; Min Tang; Franziska Michor
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more
  1 in total

1.  Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China.

Authors:  Xiaoning He; Mengqian Zhang; Jing Wu; Song Xu; Xiangli Jiang; Ziping Wang; Shucai Zhang; Feng Xie
Journal:  Patient Prefer Adherence       Date:  2021-04-15       Impact factor: 2.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.